Spots Global Cancer Trial Database for grade 2 follicular lymphoma

Every month we try and update this database with for grade 2 follicular lymphoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Systemic Mastocytosis	NCT00132015	Chronic Myelopr... Leukemia Lymphoma Nonneoplastic C... Precancerous Co...	tanespimycin	18 Years -	National Institutes of Health Clinical Center (CC)
Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma	NCT02992522	B-Cell Lymphoma... Grade 1 Follicu... Grade 2 Follicu... Grade 3a Follic... Recurrent Burki... Recurrent Diffu... Recurrent Folli... Recurrent Margi... Refractory Burk... Refractory Diff... Refractory Foll... Transformed Rec... B-Cell	Lenalidomide Obinutuzumab Venetoclax	18 Years -	Ohio State University Comprehensive Cancer Center
Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma	NCT02992522	B-Cell Lymphoma... Grade 1 Follicu... Grade 2 Follicu... Grade 3a Follic... Recurrent Burki... Recurrent Diffu... Recurrent Folli... Recurrent Margi... Refractory Burk... Refractory Diff... Refractory Foll... Transformed Rec... B-Cell	Lenalidomide Obinutuzumab Venetoclax	18 Years -	Ohio State University Comprehensive Cancer Center
TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade B-Cell Non-Hodgkin Lymphomas	NCT03410901	B-Cell Non-Hodg... Grade 1 Follicu... Grade 2 Follicu... Grade 3a Follic... Lymphoplasmacyt... Mantle Cell Lym... Marginal Zone L... Small Lymphocyt...	Anti-OX40 Antib... Laboratory Biom... Radiation Thera... TLR9 Agonist SD...	18 Years -	Stanford University
TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade B-Cell Non-Hodgkin Lymphomas	NCT03410901	B-Cell Non-Hodg... Grade 1 Follicu... Grade 2 Follicu... Grade 3a Follic... Lymphoplasmacyt... Mantle Cell Lym... Marginal Zone L... Small Lymphocyt...	Anti-OX40 Antib... Laboratory Biom... Radiation Thera... TLR9 Agonist SD...	18 Years -	Stanford University
Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell Non-Hodgkin Lymphoma	NCT01239875	Cutaneous B-cel... Extranodal Marg... Nodal Marginal ... Adult Diffuse M... Adult Diffuse S... Adult Grade III... Adult Immunobla... Adult Lymphobla... Grade 1 Follicu... Grade 2 Follicu... Grade 3 Follicu... Mantle Cell Lym... Marginal Zone L... Small Lymphocyt... Splenic Margina... Waldenstrom Mac...	dendritic cell ... cryotherapy pneumococcal po... laboratory biom... immunoenzyme te... immunohistochem... autologous dend...	18 Years - 90 Years	Mayo Clinic
TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma	NCT02927964	Grade 1 Follicu... Grade 2 Follicu... Grade 3a Follic... Recurrent Folli... Refractory Foll... Mantle Cell Lym... Marginal Zone L...	Ibrutinib Radiation Thera... TLR9 Agonist SD...	18 Years -	Stanford University
Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell Non-Hodgkin Lymphoma	NCT01239875	Cutaneous B-cel... Extranodal Marg... Nodal Marginal ... Adult Diffuse M... Adult Diffuse S... Adult Grade III... Adult Immunobla... Adult Lymphobla... Grade 1 Follicu... Grade 2 Follicu... Grade 3 Follicu... Mantle Cell Lym... Marginal Zone L... Small Lymphocyt... Splenic Margina... Waldenstrom Mac...	dendritic cell ... cryotherapy pneumococcal po... laboratory biom... immunoenzyme te... immunohistochem... autologous dend...	18 Years - 90 Years	Mayo Clinic
Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas	NCT04883437	Grade 1 Follicu... Grade 2 Follicu... Grade 3a Follic... Indolent Non-Ho... Lymphoplasmacyt... Lymphoprolifera... Mantle Cell Lym... Marginal Zone L...	Acalabrutinib Obinutuzumab Quality-of-Life... Questionnaire A...	18 Years -	Emory University
Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma	NCT05169658	Non-Hodgkin Lym... Grade 1 Follicu... Grade 2 Follicu... Grade 3a Follic... Indolent B-Cell... Marginal Zone L... Recurrent Extra... Refractory Extr...	Mosunetuzumab Obinutuzumab Polatuzumab Ved...	18 Years -	University of Washington
Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma	NCT03010358	Anemia B-Cell Prolymph... Grade 1 Follicu... Grade 2 Follicu... Grade 3a Follic... Hairy Cell Leuk... Lymphoplasmacyt... Mantle Cell Lym... Marginal Zone L... Recurrent Chron... Recurrent Small... Refractory Chro... Refractory Smal... Richter Syndrom...	Entospletinib Laboratory Biom... Obinutuzumab Pharmacological...	18 Years -	OHSU Knight Cancer Institute
Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma	NCT04450173	Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Grade 1 Follicu... Grade 2 Follicu... Grade 3a Follic...	Ibrutinib Obinutuzumab Venetoclax	18 Years -	University of California, Davis
Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma	NCT02992522	B-Cell Lymphoma... Grade 1 Follicu... Grade 2 Follicu... Grade 3a Follic... Recurrent Burki... Recurrent Diffu... Recurrent Folli... Recurrent Margi... Refractory Burk... Refractory Diff... Refractory Foll... Transformed Rec... B-Cell	Lenalidomide Obinutuzumab Venetoclax	18 Years -	Ohio State University Comprehensive Cancer Center
Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas	NCT03198026	Non-Hodgkin's L... Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Ann Abor Stage ... Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Grade 1 Follicu... Grade 2 Follicu... Grade 3a Follic... Indolent Non-ho... Stage II Spleni... Stage III Splen... Stage IV Spleni...	Ibrutinib Obinutuzumab Laboratory Biom...	18 Years -	Thomas Jefferson University
Ibrutinib in Combination With Rituximab and Lenalidomide in Treating Patients With Previously Untreated, Stage II-IV Follicular Lymphoma or Marginal Zone Lymphoma	NCT02532257	Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... CD20 Positive Grade 1 Follicu... Grade 2 Follicu... Grade 3a Follic...	Ibrutinib Laboratory Biom... Lenalidomide Rituximab	18 Years -	M.D. Anderson Cancer Center
Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell Non-Hodgkin Lymphoma	NCT01239875	Cutaneous B-cel... Extranodal Marg... Nodal Marginal ... Adult Diffuse M... Adult Diffuse S... Adult Grade III... Adult Immunobla... Adult Lymphobla... Grade 1 Follicu... Grade 2 Follicu... Grade 3 Follicu... Mantle Cell Lym... Marginal Zone L... Small Lymphocyt... Splenic Margina... Waldenstrom Mac...	dendritic cell ... cryotherapy pneumococcal po... laboratory biom... immunoenzyme te... immunohistochem... autologous dend...	18 Years - 90 Years	Mayo Clinic
Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma	NCT04257578	B-Cell Non-Hodg... Diffuse Large B... High Grade B-Ce... Primary Mediast... Transformed Fol... Grade 1 Follicu... Grade 2 Follicu... Grade 3a Follic...	Acalabrutinib Axicabtagene Ci...	18 Years -	University of Washington
Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma	NCT01000753	Adult Immunobla... Central Nervous... Childhood Immun... Grade 1 Follicu... Grade 2 Follicu... Grade 3 Follicu... Lymphoprolifera... Mantle Cell Lym... Marginal Zone L... Non-Hodgkin Lym... Primary Cutaneo... Primary Cutaneo... Small Lymphocyt...	Cytology Specim...	- 21 Years	Children's Oncology Group
TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade B-Cell Non-Hodgkin Lymphomas	NCT03410901	B-Cell Non-Hodg... Grade 1 Follicu... Grade 2 Follicu... Grade 3a Follic... Lymphoplasmacyt... Mantle Cell Lym... Marginal Zone L... Small Lymphocyt...	Anti-OX40 Antib... Laboratory Biom... Radiation Thera... TLR9 Agonist SD...	18 Years -	Stanford University
Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma	NCT02950220	B-Cell Lymphoma... Grade 1 Follicu... Grade 2 Follicu... Grade 3a Follic... Mediastinal Lym... Recurrent B-Cel... Recurrent Burki... Recurrent Diffu... Recurrent Folli... Recurrent Lymph... Recurrent Mantl... Recurrent Margi... Recurrent Walde... Refractory B-Ce... Refractory Burk... Refractory Diff... Refractory Foll... Refractory Lymp... Refractory Mant...	Ibrutinib Laboratory Biom... Pembrolizumab	18 Years -	Ohio State University Comprehensive Cancer Center
Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma	NCT03010358	Anemia B-Cell Prolymph... Grade 1 Follicu... Grade 2 Follicu... Grade 3a Follic... Hairy Cell Leuk... Lymphoplasmacyt... Mantle Cell Lym... Marginal Zone L... Recurrent Chron... Recurrent Small... Refractory Chro... Refractory Smal... Richter Syndrom...	Entospletinib Laboratory Biom... Obinutuzumab Pharmacological...	18 Years -	OHSU Knight Cancer Institute
TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma	NCT02927964	Grade 1 Follicu... Grade 2 Follicu... Grade 3a Follic... Recurrent Folli... Refractory Foll... Mantle Cell Lym... Marginal Zone L...	Ibrutinib Radiation Thera... TLR9 Agonist SD...	18 Years -	Stanford University

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: